Merck & Co. Stock News

DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demonstrating clinically meaningful reduction in disease activity in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) with active...

I'm targeting value in overlooked sectors, highlighting Merck and Federal Realty as top picks for income and upside potential. Merck offers a low 8.5x PE, a 4.3% yield, a robust drug pipeline, and resilient growth despite Gardasil headwinds and tariff pressures. Federal Realty has premier assets, rising occupancy, low tenant risk, and a 4.5% yield, trading well below historical valuation multip...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society's (ATS) 2025 International Conference in San Francisco from May 16-21. Data from nine presentations demonstrate Merck's commitment to advancing res...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results of Phase 3 KEYNOTE-B96 Trial In Patients With Platinum-Resistant Recurrent Ovarian Cancer.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG PPGL FDA Approval News Release.

Merck & Co., Inc. (NYSE:MRK ) BofA Securities 2025 Healthcare Conference May 14, 2025 1:40 PM ET Company Participants Jannie Oosthuizen - President Peter Dannenbaum - Senior Vice President, Investor Relations Marjorie Green - SVP, Head of Oncology Clinical Development Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us for this, meeting. I'm Tim Anders...

The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two types adrenal gland tumors.